scholarly article | Q13442814 |
P50 | author | Edson Antunes | Q56686201 |
Gilberto de Nucci | Q5561420 | ||
P2093 | author name string | Renato Faro | |
Ana Maria Aparecida Guaraldo | |||
Marcos Zanfolin | |||
Eugênio G Araujo | |||
P433 | issue | 3 | |
P304 | page(s) | 391-395 | |
P577 | publication date | 2006-03-01 | |
P1433 | published in | Journal of Cardiovascular Pharmacology | Q2125808 |
P1476 | title | Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats | |
P478 | volume | 47 |
Q37193830 | Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells |
Q45664565 | BAY 41-2272 Treatment Improves Acetylcholine-Induced Aortic Relaxation in L-NAME Hypertensive Rats. |
Q35204828 | Cardiac NO signalling in the metabolic syndrome |
Q37420916 | Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics |
Q35619526 | Effect of nitric oxide synthase inhibition on intrarenal oxygenation as evaluated by blood oxygenation level-dependent magnetic resonance imaging |
Q28482185 | Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade |
Q27692662 | Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. |
Q24656131 | NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential |
Q35375986 | NOX1, 2, 4, 5: counting out oxidative stress |
Q38594785 | New medical therapies for heart failure |
Q37766747 | Novel therapeutic targets for hypertension |
Q36532454 | Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling |
Q58766337 | Role of Nitric Oxide in the Cardiovascular and Renal Systems |
Q35010064 | Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease |
Q38093420 | Stimulators of soluble guanylyl cyclase: future clinical indications |
Q36380981 | The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy |
Search more.